Management of Interstitial Cystitis/Bladder Pain Syndrome
Begin with behavioral modifications and non-pharmacologic therapies, then add oral medications (amitriptyline or cimetidine preferred), with the critical exception that patients with Hunner lesions should undergo immediate cystoscopy and lesion-directed treatment rather than failing through conservative therapies first 1.
Initial Diagnostic Imperative
Before initiating treatment, you must determine if Hunner lesions are present, as this fundamentally changes management. Perform cystoscopy early in patients suspected of having these lesions—they respond well to directed treatment and should not be required to fail behavioral or medical therapies first 1. This represents a major shift in thinking: phenotyping drives treatment selection.
Treatment Algorithm by Category
Behavioral/Non-Pharmacologic Interventions (Start Here for Non-Hunner Patients)
- Dietary modifications: Eliminate known bladder irritants through systematic elimination diet
- Fluid management: Adjust concentration/volume of urine through strategic hydration or restriction
- Pelvic floor physical therapy: Focus on muscle relaxation, not strengthening exercises which may worsen symptoms 1
- Stress management: Implement meditation, imagery, and coping techniques for flare management 1
- Avoid triggers: Tight clothing, certain exercises, manage constipation aggressively
- Bladder training: Urge suppression techniques combined with scheduled voiding
Oral Pharmacologic Therapy (Add When Behavioral Measures Insufficient)
Amitriptyline (Grade B evidence): Start 10 mg nightly, titrate gradually to 75-100 mg as tolerated. Superior to placebo but expect adverse effects (sedation, drowsiness, nausea) that may compromise quality of life 1.
Cimetidine (Grade B evidence): Clinically significant improvement in pain and nocturia with no reported adverse effects—an underutilized option 1.
Hydroxyzine (Grade C evidence): Consider especially in patients with systemic allergies. Expect short-term sedation and weakness 1.
Pentosan polysulfate (PPS): FDA-approved but you must counsel patients about macular damage and vision-related injuries before starting or continuing 1. Evidence is contradictory on effectiveness, and given the serious ocular risks, many patients will choose not to start or to discontinue this medication 2. The risk-benefit discussion is mandatory.
Pain Management Considerations
Do not rely on pain management alone—it's insufficient as monotherapy 1. Treat underlying bladder symptoms concurrently. Avoid chronic opioids except after informed shared decision-making with periodic reassessment for efficacy, adverse events, and potential abuse 1. Prioritize non-opioid alternatives.
Bladder Instillations (For Refractory Cases)
Intravesical therapies include glycosaminoglycans or dimethyl sulfoxide 3. These represent escalation for patients not responding to oral therapies.
Interventional Procedures (Advanced Refractory Disease)
- Hydrodistension
- OnabotulinumtoxinA intravesical injections
- Sacral neuromodulation 3
Major Surgery (Last Resort Only)
Reserved for carefully selected patients with severe, documented bladder-centric disease 1, 3. This is not a first-line consideration and requires rigorous phenotypic selection.
Critical Pitfalls to Avoid
Do not treat all IC/BPS patients the same—the 2022 AUA guideline explicitly abandoned the tiered treatment approach because IC/BPS is heterogeneous 1. Phenotyping (bladder-centric vs. sensitization phenotype) determines optimal therapy 4.
Do not miss Hunner lesions—these patients have a distinct inflammatory pathophysiology requiring different management 5. Cystoscopy is the only reliable diagnostic method 1.
Do not continue PPS without discussing ocular risks—this is a clinical principle mandate, not optional 1.
Do not use pelvic floor strengthening exercises—these may worsen symptoms; focus on relaxation techniques instead 1.
Multimodal Approach
Concurrent therapies may be offered 1. Combine behavioral modifications with oral medications, add bladder instillations if needed, and consider procedures only for truly refractory cases. The key is individualization based on phenotype, symptom severity, and treatment response, with regular reassessment using baseline voiding logs and pain scores 1.